Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Meningitis B Vaccine | Bexsero | 4.8 Undesirable effects | Blood and lymphatic system disorders, Lymphadenopathy | Mar,2024 |
| COVID-19 Vaccine Moderna | Spikevax | 4.4 Special warnings and precautions for use | Altered immunocompetence | Mar,2024 |
| Lercanidipine | Lercadip | 4.4 Special warnings A185:C185and precautions for use | Sick-sinus syndrome, | Mar,2024 |
| Etanercept | Enbrel | 4.8 Undesirable effects | Glomerulon ephritis | Mar,2024 |
| Pantoprazole | Pantozol | "4.3 Contraindications 4.4 Special warnings and precautions for use 4.5 Interaction with other medicinal products and other forms of interaction" | "Co-administer Rilpivirine Gastric malignancy, Sub-acute cutaneous lupus erythematosus HIV protease inhibitors " | Feb,2024 |
| Cyclophosphamide | Endoxan | "4.4. Special warnings and precautions for use 4.5 Interaction with other medicinal products and other forms of interaction 4.6 Fertility, pregnancy and lactation" | "Dose adjustment due to myelosuppression is recommended , Men treated with cyclophosphamide should be informed about sperm preservation prior to treatment Clozapine, CYP2B6 and CYP3A4 inhibitors, Grapefruit Contraception in males and females" | Feb,2024 |